Lowe HC - Search Results

1

Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis.

Lowe HC, Fahmy RG, Kavurma MM, Baker A, Chesterman CN, Khachigian LM. Lowe HC, et al. Circ Res. 2001 Oct 12;89(8):670-7. doi: 10.1161/hh2001.097867. Circ Res. 2001. PMID: 11597989

2

Catalytic antisense DNA molecules targeting Egr-1 inhibit neointima formation following permanent ligation of rat common carotid arteries.

Lowe HC, Chesterman CN, Khachigian LM. Lowe HC, et al. Thromb Haemost. 2002 Jan;87(1):134-40. Thromb Haemost. 2002. PMID: 11848443

3

Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation.

Francis DJ, Parish CR, McGarry M, Santiago FS, Lowe HC, Brown KJ, Bingley JA, Hayward IP, Cowden WB, Campbell JH, Campbell GR, Chesterman CN, Khachigian LM. Francis DJ, et al. Among authors: lowe hc. Circ Res. 2003 May 2;92(8):e70-7. doi: 10.1161/01.RES.0000071345.76095.07. Epub 2003 Apr 10. Circ Res. 2003. PMID: 12690039

4

DNAzymes targeting the transcription factor Egr-1 reduce myocardial infarct size following ischemia-reperfusion in rats.

Bhindi R, Khachigian LM, Lowe HC. Bhindi R, et al. Among authors: lowe hc. J Thromb Haemost. 2006 Jul;4(7):1479-83. doi: 10.1111/j.1538-7836.2006.02022.x. J Thromb Haemost. 2006. PMID: 16839341 Free article.

5

Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2.

Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM. Santiago FS, et al. Among authors: lowe hc. Am J Pathol. 1999 Mar;154(3):937-44. doi: 10.1016/S0002-9440(10)65341-2. Am J Pathol. 1999. PMID: 10079272 Free PMC article.

6

New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury.

Santiago FS, Lowe HC, Kavurma MM, Chesterman CN, Baker A, Atkins DG, Khachigian LM. Santiago FS, et al. Among authors: lowe hc. Nat Med. 1999 Nov;5(11):1264-9. doi: 10.1038/15215. Nat Med. 1999. PMID: 10545992

7

Coating stents with antirestenotic drugs: the blunderbuss or the magic bullet?

Lowe HC, Khachigian LM. Lowe HC, et al. Circulation. 2002 Jan 29;105(4):E29. Circulation. 2002. PMID: 11815443 No abstract available.

8

Novel and emerging therapies in cardiology and haematology.

Pimanda JE, Lowe HC, Hogg PJ, Chesterman CN, Khachigian LM. Pimanda JE, et al. Among authors: lowe hc. Curr Drug Targets Cardiovasc Haematol Disord. 2003 Jun;3(2):101-23. doi: 10.2174/1568006033481465. Curr Drug Targets Cardiovasc Haematol Disord. 2003. PMID: 12769638 Review.

9

Animal models of vulnerable plaque. Clinical context and current status.

Lowe HC, Jang IK, Khachigian LM. Lowe HC, et al. Thromb Haemost. 2003 Nov;90(5):774-80. doi: 10.1160/TH03-06-0374. Thromb Haemost. 2003. PMID: 14597970 Review.

10

Fibroblast growth factor 2 and the transcription factor Egr-1 localise to endothelial cell microvascular channels in human coronary artery occlusion.

Bhindi R, Brieger D, Ishii H, Di Girolamo N, Kumar RK, Khachigian LM, Lowe HC. Bhindi R, et al. Among authors: lowe hc. Thromb Haemost. 2005 Jan;93(1):172-4. Thromb Haemost. 2005. PMID: 15875316 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

131 results

Search Page

Filters